DIRS.INFO The most relevant business & tech news

☆ Why the hydrogen tax credit has become a lightning rod for controversy
▼ + stars: | 2023-10-13 | by ( Catherine Clifford | In Catclifford | ) www.cnbc.com time to read: +16 min

The proposed tax credit, 45V, is meant to turbocharge the production of low-emissions hydrogen. "The IRA's section 45V production tax credit is the most generous clean hydrogen subsidy in the world," Jesse Jenkins, professor of macro-scale energy systems at Princeton University, told CNBC. John Macdougall | Afp | Getty ImagesThe adjudication of the hydrogen tax credit has become about more than just the hydrogen tax credit, too. The amount of the hydrogen tax credit, which is available for 10 years, depends on the emissions generated in making hydrogen. If hydrogen is produced without releasing any carbon emissions, the tax credit is maxed out at $3 per kilogram of hydrogen.

Persons: that's, It's, Jesse Jenkins, John Macdougall, Wilson Ricks, Jenkins, Ricks, Rachel Fakhry, electrolyzers, Andriy Onufriyenko, Eric Guter, Josef Kallo, H2FLY, Guter, Phil Musser, Shannon Angielski, Angielski, Shi, Fakhry Organizations: Istock, Treasury, Princeton University, CNBC, Daimler Truck Holding, Afp, Getty, Energy, Research, Princeton, Natural Resources Defense Council, Power, Singularity, Air Products, Bloomberg, Air, Products, Hydrogen Company, European, EU, NextEra Energy, Hydrogen Future Coalition, BP, Duke Energy, Exxon Mobile, General Electric, Siemens Energy, American, Shell, Hydrogen, Coalition Locations: Biden's, United States, U.S, Berlin, additionality, Maribor, Slovenia, Oxagon, Saudi Arabia, Wilbarger County , Texas

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ I get stories every day from patients about how Mounjaro is benefiting their lives, Eli Lilly CEO David Ricks
▼ + stars: | 2023-08-08 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailI get stories every day from patients about how Mounjaro is benefiting their lives, Eli Lilly CEO David RicksEli Lilly CEO David Ricks joins 'Mad Money' host Jim Cramer to talk the recent stock pop, Eli Lilly weight-loss drug and more.

Persons: Eli Lilly, David Ricks Eli Lilly, David Ricks, Jim Cramer

☆ Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap
▼ + stars: | 2023-08-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.

Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain

☆ Eli Lilly CEO David Ricks: Almost one billion people could benefit from obesity medications
▼ + stars: | 2023-08-08 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Eli Lilly CEO David Ricks: Almost one billion people could benefit from obesity medicationsEli Lilly CEO David Ricks joins 'Mad Money' host Jim Cramer to talk the recent stock pop, Eli Lilly weight-loss drug and more.

Persons: Eli Lilly, David Ricks, Jim Cramer

☆ Eli Lilly CEO on meeting demand for expected obesity drug Mounjaro: 'It’s my top priority'
▼ + stars: | 2023-08-08 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Eli Lilly CEO Dave Ricks told CNBC's Jim Cramer on Tuesday his top priority was to meet demand for the company's drug, Mounjaro, which is currently only approved by the Food and Drug Administration to treat diabetes but is expected to soon be cleared to treat obesity, along with other health conditions. Eli Lilly stock surged 15% Tuesday after its better-than-expected earnings report. He likened obesity to depression, noting Eli Lilly's role in manufacturing Prozac, the depression drug. We know that's not true, there's something called clinical depression," Ricks said. I think in five, 10 years we'll look back and think about chronic weight management and obesity the same way."

Persons: Eli Lilly, Dave Ricks, CNBC's Jim Cramer, Ricks, FactSet —, Eli Lilly's Organizations: Food and Drug Administration Locations: North Carolina

☆ Obesity drugs take brakes off Big Pharma’s growth
▼ + stars: | 2023-08-08 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

That’s what Eli Lilly (LLY.N) did in the second quarter, thanks to demand for its diabetes and weight loss drug Mounjaro. While doctors are currently free to prescribe Mounjaro for obesity, insurers and governments typically won’t pay for what some still insist is a vanity treatment. Even so a regulatory green light, and clear evidence that these drugs have tangible health benefits, will help loosen purse strings. The brakes are off these firms’ growth, and investors are counting on them remaining so. Mounjaro, the company’s diabetes drug, brought in revenue of $980 million, compared to $16 million a year ago.

Persons: Eli Lilly, LLY.N, Lilly, That’s, David Ricks, Mounjaro, Peter Thal Larsen, Sharon Lam Organizations: Reuters, Novo Nordisk, U.S . Food, Drug Administration, Merck, Investors, Thomson Locations: Danish, U.S, Novo

☆ A key bank stock soars, but Cramer sticks to his discipline
▼ + stars: | 2023-07-18 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Watch Morgan Stanley Bank stocks climbed higher Tuesday, as Club holding Morgan Stanley (MS) delivered an earnings beat. "My conviction is that Morgan Stanley stock goes higher," Jim Cramer said Tuesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Morgan Stanley, Eli Lilly, David Ricks, Jim, Jim Cramer's Organizations: CNBC, Morgan Stanley Bank, Club, Nasdaq, Ford Our automaker, Ford Locations: U.S

☆ This cyber security stock is clawing back gains after a week of losses, making it a top mover in the portfolio Monday
▼ + stars: | 2023-07-17 | by ( ) www.cnbc.com time to read: 1 min

This cyber security stock is clawing back gains after a week of losses, making it a top mover in the portfolio MondayEli Lilly CEO, David Ricks discussed the company's positive results from its latest Alzheimer's study. While LLY is a direct play into treating the disease, we have another stock that will also benefit from Alzheimer's treatments on the infrastructure side of the health care business.

Persons: Eli Lilly, David Ricks

☆ Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
▼ + stars: | 2023-07-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer's treatment, donanemab, and expects the agency to make a decision by the end of the year. "The earlier you begin to use the drug perhaps the more slowing that can be," Eli Lilly CEO David Ricks said in an interview on CNBC's "Squawk on the Street" on Monday. Eli Lilly is among the pharmaceutical companies racing to market new treatments for the disease after Eisai and Biogen's drug Leqembi won FDA approval this month. The agency's signoff on Leqembi was a milestone in the treatment of Alzheimer's, even though the drug and donanemab aren't cures. An FDA approval of Eli Lilly's donanemab would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's, the fifth-leading cause of death for adults over 65.

Persons: Eli Lilly, Monday, David Ricks, Leqembi, Eli Lilly's donanemab, Ricks Organizations: U.S, Food, Drug, Medicare, Services, CNBC Locations: Leqembi

☆ Reading the Tea Leaves on the End of the War in Ukraine
▼ + stars: | 2023-06-27 | by ( Thomas E. Ricks | ) www.nytimes.com time to read: +2 min

The Russian invasion of Ukraine that began in February last year has led to the biggest war in Europe in many generations. Within a month of the war’s onset, it had already become “a [foul]-up of historic proportions,” as one veteran Ukraine correspondent recently put it. Five weeks after the invasion, Putin’s spokesman claimed that Ukraine’s military was “largely destroyed.”But a war intended to undercut Ukraine’s leaders and NATO has instead strengthened both. Less noticed in the West is how Russia’s war has also alienated former Soviet nations such as Azerbaijan and Kazakhstan. Just before the war, the Scottish American historian Niall Ferguson wrote that Ukraine would receive “no significant military support from the West” and speculated on the location of Putin’s victory parade.

Persons: —, Don, Vladimir Putin, Izvestia, Niall Ferguson Organizations: Wagner, NATO, Scottish, West Locations: Ukraine, Europe, Russian, Rostov, mull, Bulgaria, Romania, Azerbaijan, Kazakhstan, Scottish American, Ukrainian

☆ CEOs do matter when picking stocks. 5 things we look for in a leader and examples from our portfolio
▼ + stars: | 2023-06-21 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +16 min

It's not unusual for a company's stock price to soar — or sink — on news of a CEO shakeup. So, CEOs matter when picking stocks — and at the Club, these are the five things we look for when evaluating the leaders of our holdings. A stock's day-to-day and even month-to-month performance may not truly reflect how well a CEO is leading a company. Trust has value, and the stocks of companies led by reputable CEOs with competent management teams can trade at premium valuations. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Mary Dillon, Locker, J im Cramer, buybacks, Rainer Blair, —, Kevin Johnson, Marc Benioff, Mark Zuckerberg, Zuckerberg, we've, Bruce Broussard, Humana, Jeff Smith's, Craig Jelinek, who's, that's, Jelinek, it'd, Andy Jassy, Tim Cook, he's, Cook, Jim Cramer's, Dan Schulman, Sanjiv Lamba, Linde, Lamba, Eli Lilly, Dave Ricks, Eli Lilly's, Jim, Lilly, Jim Farley, Farley, Elon Musk's Tesla, Ford, LLY, Jim Cramer, Spencer Platt Organizations: Club, McKinsey & Co, Natural Resources, GE Life Sciences, SVB Securities, Starbucks, Humana, Bain & Co, Costco, CNBC, Apple, Amazon's, Football, MGM, Management, PayPal, Linde, LIN, Ford Motor, Wall, EV, Ford, The New York Stock Exchange, Financial, Getty Locations: U.S, Manhattan, New York City

☆ The CEO of pharma giant Eli Lilly shares 3 ways AI could transform his industry
▼ + stars: | 2023-06-15 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +5 min

The CEO of Eli Lilly said he expects AI to massively change the productivity of the workplace. According to David Ricks, the CEO of the pharma giant Eli Lilly, the technology has the potential to upend the industry. Ricks told Insider that AI is "one of the most exciting technological moves" he's seen in a long time. Three ways Lilly wants to use AIRicks said he sees three main ways Lilly and the larger biopharma space could use AI. In May, Lilly announced a $250 million partnership with pharmaceutical-technology company XtalPi to uncover new potential drugs using AI.

Persons: Eli Lilly, David Ricks, Ricks, It's, Lilly Organizations: Biotech, pharma, Morning

☆ Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David Ricks
▼ + stars: | 2023-06-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailVast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David RicksEli Lilly CEO David Ricks joins CNBC's Bertha Coombs and 'The Exchange' live from the World Medical Innovation Forum to discuss Eli Lilly's alzheimer's treatment, concerns over coverage reimbursement schemes, and upcoming drug price negotiations.

Persons: Eli Lilly, David Ricks Eli Lilly, David Ricks, Bertha Coombs, Eli Lilly's

☆ Eli Lilly CEO says Medicare price negotiations could harm drug development
▼ + stars: | 2023-06-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly CEO David Ricks on Tuesday said Medicare price negotiations, which aim to cut costs for older Americans, could potentially harm drug development. "I'm really worried about the harm this will do to new cures and possibilities in medicine," Ricks said in an interview on CNBC's "The Exchange." He's the latest pharmaceutical executive to publicly blast the provision and law at large, which will likely reduce company profits. Global drugmaker Merck last week sued the Biden administration over Medicare price negotiations in a bid to weaken the program. Under the IRA provision, Medicare can start negotiating prices on small-molecule drugs as early as nine years after they receive Food and Drug Administration approval, compared with 13 years for biologics.

Persons: Eli Lilly, David Ricks, I'm, Ricks Organizations: Biden, Global drugmaker Merck, Drug Administration

☆ Opinion | If You’re Reading This, You’re Probably ‘WEIRD’
▼ + stars: | 2023-05-26 | by ( The Ezra Klein Show | ) www.nytimes.com time to read: +83 min

You’re probably very weird, and not just for all the obvious reasons you’re thinking of. Because, obviously, there’s going to be some overlap in the curve here. How you’re going to behave with your professor is quite different than how you’re going to behave with your friends. But it’s really kind of faceless, and you’re not really helping anybody you know. I think things are dynamic, and directions are changing, and that sort of thing.

☆ Carbon Accounting Changes Could Lift Corporate Greenhouse-Gas Emissions
▼ + stars: | 2023-05-18 | by ( Dieter Holger | ) www.wsj.com time to read: +5 min

Changes to emissions accounting rules are being considered that could significantly increase carbon footprints for companies claiming to use 100% renewable power in their efforts to decarbonize. How companies tally greenhouse-gas emissions from their electricity purchases—so-called Scope 2 emissions—was the most popular issue in a recent consultation on updating widely used GHG Protocol carbon accounting rules. A recent review by carbon management firm FlexiDAO of 22 multinationals that bought renewable electricity across 27 countries found that they could be underestimating their electricity emissions by close to 50% under the current system. The GHG Protocol secretariat is reviewing the more than 1,400 survey responses, around 400 of which mentioned Scope 2. Other areas of focus were emissions in the value chain, or so-called Scope 3 emissions, market-based accounting approaches, and corporate accounting and reporting standards.

☆ Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge
▼ + stars: | 2023-05-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Sen. Bernie Sanders, the committee's chair, asked Ricks and the CEOs of Novo Nordisk and Sanofi to commit to "never increase the price of any insulin drug again." Meanwhile, Novo Nordisk CEO Lars Fruergaard Jørgensen said the Danish company is committed to limiting price increases to "single digits." Net price refers to the amount insurers pay for an insulin drug after discounts and rebates. Sanofi said it plans to cut the price of its most popular insulin drug, Lantus, by 78% and reduce the list price of its short-acting insulin, Apidra, by 70%. At the hearing, Sanders called those actions "good news" and a result of public pressure.

☆ Positive Alzheimer's drug trial data pushes Eli Lilly shares to another all-time high and brightens our outlook
▼ + stars: | 2023-05-03 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. The FDA granted accelerated approval to an anti-amyloid drug — developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB) — in early January. For Eli Lilly, specifically, Seigerman said the donanemab data appears to be a "home run." Eli Lilly said two participants in the Phase 3 trial died due to ARIA side effects, while a third patient did after a serious ARIA incident. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

The drug, donanemab, met all goals of the trial. "These are the strongest phase 3 data for an Alzheimer's treatment to date," said Maria Carrillo, chief science officer for the Alzheimer's Association. In the donanemab treatment group, Lilly said brain swelling, a known side effect of drugs of this type, occurred in 24% of the participants, with 6.1% experiencing symptoms. In the Leqembi Phase 3 trial, the drug was associated with brain swelling in nearly 13% of its study participants. It also said 47% of donanemab patients in the 18-month trial had no disease progression at 12 months, compared with 29% of the placebo group.

☆ Sales, spins and splits — what are the differences and why do they matter for investors like us?
▼ + stars: | 2023-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +20 min

Investors may get one share in the spun-out entity for every share of the parent company they owned. What's left of J & J will be focused on pharmaceuticals and medical technologies, which were responsible for over 84% of the company's total 2022 revenue of $94.94 billion. It underscores that once free of the parent company tethers a divested company can chart its own destiny. Those priorities may not have necessarily been wrong when considering J & J as the overall enterprise. We believe J & J and Danaher are poised to deliver two more examples.

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

Patients who took Eli Lilly 's weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their body weight, the company said in clinical trial results released Thursday. Eli Lilly plans to complete its application for Food and Drug Administration approval of the drug in the coming weeks and expects regulatory action as early as later this year. The FDA approved tirzepatide for Type 2 diabetes last year, but the drug is not cleared for weight loss. The approval would open "up the opportunity for many more people to benefit from tirzepatide," Eli Lilly CEO David Ricks said Thursday on CNBC's "Squawk Box." He added that the drug sets a "new bar for weight loss and people with diabetes."

☆ Watch CNBC's full interview with Eli Lilly CEO David Ricks
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Eli Lilly CEO David RicksEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the drugmaker's Q1 earnings results, which missed on earnings but beat on revenue, and the company outlook for the rest of the year.

☆ Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investment
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investmentEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the drugmaker's Q1 earnings results, which missed on earnings but beat on revenue, and the company outlook for the rest of the year.

Search resuls for: "Ricks"

25 mentions found